Synairgen (SYGGF)

Executive Summary

Synairgen is a UK-based respiratory biotech developing SNG001, an inhaled formulation of interferon beta (IFN-β) designed to boost innate antiviral defenses in the lungs. With a broad-spectrum mechanism, SNG001 has potential against severe viral lung infections, including COVID-19 and influenza. The company has completed Phase 2 trials in COVID-19, showing signals of efficacy in reducing progression to severe disease, and is preparing for pivotal trials. As a private company focused on respiratory biologics, Synairgen represents a high-risk, high-reward opportunity in the antiviral space. Its valuation of ~$110M reflects early-stage status and the need for further clinical validation.

Upcoming Catalysts (preview)

• Q3 2026Phase 2b/3 trial initiation in influenza or other respiratory viruses50% success
• H2 2026Strategic partnership or licensing deal for SNG00140% success
• Q4 2026Regulatory guidance for pivotal trial design from MHRA or FDA60% success